H|\^&|||AxSYM^3.60^8472^H1P1O1R1C1Q1L1M1|||||||P|1|20020622143351
P|1||||DR MARYANTI
O|1||3818^A^11|^^^25^LH^UNDILUTED|R||||||||||||||||||||F
R|1|^^^25^LH^UNDILUTED^^F|47.69|mIU/mL||EX||F||ADMIN||20020622112234
R|2|^^^25^LH^UNDILUTED^^P|287.20|Rate||||F||ADMIN||20020622112234
L|1
H|\^&|||AxSYM^3.60^8472^H1P1O1R1C1Q1L1M1|||||||P|1|20020622143352
P|1||||DR MARYANTI
O|1||3818^A^11|^^^208^hTSH_II^UNDILUTED|R||||||||||||||||||||F
R|1|^^^208^hTSH_II^UNDILUTED^^F|1.233|uIU/mL||||F||ADMIN||20020622112435
R|2|^^^208^hTSH_II^UNDILUTED^^P|37.05|Rate||||F||ADMIN||20020622112435
L|1
vitec2 debug frame:mtrsl|iiV2|is00001A0FD287|itSU|pi22116897|pnNy Wiwit , Ewoningsih |plRS. Mawaddah Medika Mojokerto |p2RS. Mawaddah Medika Mojokerto |ppdr. Endah Sp.PD|p5dr. Endah Sp.PD |si|s01908|ssDarah|s5Darah|s104/23/2026|s304/23/2026|ci2B260421025|c01908|ctDarah|cnDarah|ta|rtAST-N806|rr735074|t4F|t5Final|r104/23/2026|r210:57|r304/23/2026|r418:58|te03/13/2027|th04/23/2026|tk10:57|td04/23/2026|tm18:58|nc1|ndESBL DETECTED|t11|o1esccol|o2Escherichia coli|acConsistent|afAMINOGLYCOSIDES|apRESISTANT GEN TOB (ANT(2''))|apRESISTANT GEN TOB NET (AAC(3)-II)|apRESISTANT GEN (AAC(3)-I)|apRESISTANT GEN TOB NET (AAC(3)-IV)|apRESISTANT GEN TOB NET AMI|afQUINOLONES|apRESISTANT|afTRIMETHOPRIM/SULFONAMIDES|apRESISTANT|afFURANES|apWILD|afBETA-LACTAMS|apEXTENDED SPECTRUM BETA-LACTAMASE|ra|a1esbl|a2ESBL|a3Pos|a4+|an+|ra|a1am|a2Ampicillin|a3>=32|a4R|anR|ra|a1ams|a2Ampicillin/Sulbactam|a3>=32|a4R|anR|ra|a1tzp|a2Piperacillin/Tazobactam|a38|a4S|anS|ra|a1cz06|a2Cefazolin (urine)|a3>=32|a4R|anR|ra|a1cz03|a2Cefazolin (other)|a3>=32|a4R|anR|ra|a1taz|a2Ceftazidime|a3>=32|a4R|anR|ra|a1ctr|a2Ceftriaxone|a3>=64|a4R|anR|ra|a1fep|a2Cefepime|a3>=32|a4R|anR|ra|a1etp|a2Ertapenem|a30.25|a4S|anS|ra|a1mem|a2Meropenem|a3<=0.25|a4S|anS|ra|a1gm|a2Gentamicin|a3>=16|a4R|anR|ra|a1cip|a2Ciprofloxacin|a3>=4|a4R|anR|ra|a1lev|a2Levofloxacin|a3>=8|a4R|anR|ra|ar|a1ftn|a2Nitrofurantoin|a3<=16|a4S|anS|ra|a1sxt|a2Trimethoprim/Sulfamethoxazole|a3>=320|a4R|anR|ra|ad|a1amx|a2Amoxicillin|a3|a4R|an|ra|ad|a1tax|a2Cefotaxime|a3|a4R|an|ra|ad|a1mev|a2Meropenem/Vaborbactam|a3|a4S|an|zz|8





Pada pengsian JPA AGREEMENT 
1. Bagaimana cara memberikan persenan jpa jika pemeriksaannya jpanya ingin disendirikan, misalnya lab dan mikro, contoh lab itu diberi jpa 5%, mikro 2%, bagaimana cara settingnya di agreement?



replicate-do-table = one.t_bacteria 
replicate-do-table = one.t_antibiotic
replicate-do-table = one.t_antibiotic_group
replicate-do-table = one.t_type_pengecatan
replicate-do-table = one.t_result_pengecatan
replicate-do-table = one.t_bahan_mikro






pasien sudah pembayaran, ternyata pasien tersebut harusnya dapat diskon, bagaimana cara memberi diskonnya














FO-05 Laporan detail pemeriksaan
- Tambahkan Filter instansi

Laporan Penagihan pada menu keuangan - Penagihan
ingin ditampilkan di regional dengan parameter startdate enddate, cabang dan kel pelanggan, status lunas

Front Office tambah tanggal akhir di kasir

FO-010 Laporan Pendapatan minta ditambahkan filter kel.pelanggan

KEU33 sedang dibahas mba kiky dan bu kori

pelunasan piutang rincian ingin dibahas

FO-07 ingin buat report baru yang ada filter instansinya







user tidak kurir tapi bisa login kurir

laporan PENGIRIMAN LAINNYA
 tidak muncul nama autorizednya